Futura Medical has announced a strategic US commercial partnership for its erectile dysfunction gel Eroxon alongside encouraging clinical data for a women’s sexual health product, signaling a pivotal shift in the company’s business model and pipeline progress.
The company selected Market Performance Group (MPG) as its new US commercial partner for Eroxon, a move that marks a transition away from traditional licensing. Under the agreement, MPG will handle commercial execution, advertising, distribution and customer operations while Futura retains control over brand strategy, promotional investment and product supply. Chief executive Alex Duggan explained that the partnership reflects a more actively managed hybrid model, noting that Eroxon already generates around $5 million in trade level sales and provides a strong foundation for growth in the US consumer healthcare market.
In parallel, Futura reported encouraging results from two studies of its women’s sexual health candidate WSD4000. A home user trial involving 228 women showed that 77% reported an improved sexual experience after initial use, rising to 84% after four uses. Overall, 68% of participants said they would give the product a four or five star rating if commercially available. A separate placebo controlled “sham” study involving 33 women demonstrated a statistically significant difference between WSD4000 and the inactive control, providing confidence for the planned pivotal clinical trial. Head of R&D Ken James noted that the product was well tolerated, with 84% of women liking its sensory feel.
Next Steps and Regulatory Pathway
Futura plans to begin a Phase 3 clinical programme for WSD4000, subject to funding. Regulatory submissions are expected after completion, with a potential launch targeted for early 2028 in both the US and Europe. Duggan called the results “incredibly positive” and said they significantly de risk the path toward a pivotal trial. The company also aims to build on its broader product portfolio and growth ambitions, with Eroxon serving as an immediate priority in the US market under the new MPG partnership.
Looking ahead, Futura’s hybrid commercial strategy and promising clinical data position the company to address significant unmet needs in sexual health. With a clear regulatory roadmap and a strengthened US market presence, the outlook for both Eroxon and WSD4000 appears increasingly bright for patients and investors alike.